ECOG-ACRIN opens NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

ECOG-ACRIN Cancer Research Group and Caris Life Sciences announced a multi-year research collaboration wherein Caris is pairing its genomic, transcriptomic, and proteomic profiling, advanced artificial intelligence and machine learning algorithms with ECOG-ACRIN’s research capabilities.

October 25, 2024

Vol.50 No.40

Clinical

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

If clinical research were anything like fly fishing, the scientific question that EA3163 trial attempted to answer might be considered “the one that got away”.

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

The Robert J. Kleberg Jr. and Helen C. Kleberg Foundation awarded a $1 million grant to support research at Vanderbilt aimed at dramatically expanding the efficacy of immunotherapy for colorectal cancer.

October 04, 2024

Vol.50 No.37

Regulatory News

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

The FDA Oncologic Drugs Advisory Committee on Sept. 26 voted that PD-L1 inhibitors should not be indicated for patients with PD-L1-negative gastric/gastroesophageal junction adenocarcinoma and esophageal squamous cell carcinoma.

Group chairs propose funding strategy to jump-start correlative studies

The National Academy of Medicine recognized the value of correlative science in publicly funded clinical trials in 2010, recommending “the incorporation of innovative science into cancer clinical trials through the support and use of biorepositories.”

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

ECOG-ACRIN opens NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

YOU MAY BE INTERESTED IN

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications

Group chairs propose funding strategy to jump-start correlative studies

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Renew today!

Subscriber content

Login

ECOG-ACRIN opens NCI-MATCH treatment arm for dMMR and LAG-3-positive cancers as it continues to locate patients with BRAF mutations

YOU MAY BE INTERESTED IN

ECOG-ACRIN, Caris collaborate on interrogating TAILORx breast cancer trial

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer

Vanderbilt receives $1M grant to fund immunotherapy research in CRC

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitorsVote applies across drugs and indications

Group chairs propose funding strategy to jump-start correlative studies

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

Login

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors
Vote applies across drugs and indications